Cécile Loaec

Cécile Loaec

Auto-generated profile, based on publicly available information

Cécile Loaec

Institut de Cancérologie de l'Ouest, Saint Herblain, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2024 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
BBBarnabe Bouvarel
Barnabe Bouvarel
OCOliver Colomban
Oliver Colomban
JFJean-Sebastien Frenel
Jean-Sebastien Frenel
CLCécile Loaec
Cécile Loaec
CBCharlotte Bourgin
Charlotte Bourgin
JCJean Marc Classe
Jean Marc Classe
Objectives The modeled CA-125 elimination constant K (KELIM) is a pragmatic early marker of tumor chemosensitivity in ovarian cancer patients treated with neoadjuvant chemotherapy before interval surgery. The primary objective of this study was to assess the prognostic value of KELIM regarding the feasibility of complete surgery, and secondary objectives were to assess the prognostic value of KELIM for the risk of a platinum resistant relapse, progression free survival, and overall survival. Methods The study was based on a retrospective cohort of 284 patients treated for an advanced serous high grade ovarian cancer, International Federation of Gynecology and Obstetrics (FIGO) stages III–IV, with neoadjuvant chemotherapy, followed by interval surgery, in a comprehensive cancer center. CA-125 concentrations at baseline and during neoadjuvant chemotherapy were collected. The KELIM predictive value regarding the tumor radiological response rate, likelihood of complete surgery, risk of subsequent platinum resistant relapse, progression free survival, and overall survival were assessed with univariate and multivariate tests. Results In 232 patients, KELIM was an independent and major predictor of the probability of complete surgery and survival. The final logistic regression model, including KELIM (odds ratio (OR) 0.36, 95% confidence interval (CI)0.16 to 0.73, p=0.006) and complete surgery (no vs yes, OR 0.29, 95% CI 0.15 to 0.53, p<0.001), highlighted the complementary impact of chemosensitivity and surgical outcome relative to the complete surgery. In the multivariate analysis, KELIM and complete surgery were significantly associated with a lower risk of early relapse. In the case of an unfavorable KELIM, when surgical efforts allowed complete cytoreduction, median overall survival was similar to that reported in the case of a favorable KELIM (46.3 months (range 34.6–60.3) vs 46.5 months (range 40.6–68.7), respectively). Conclusion Primary tumor chemosensitivity, assessed by the modeled CA-125 KELIM, calculated during neoadjuvant chemotherapy, is a major parameter to consider for decision making regarding interval surgery. Complementary to the RECIST score and laparoscopy, this non-invasive tool, available online, helps tailor the interval surgery strategy according to patient tumor chemosensitivity.

1 February 2021 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
MGMarie-Mélanie Gac
Marie-Mélanie Gac
CLCécile Loaec
Cécile Loaec
JSJohanna Silve
Johanna Silve
EVEdouard Vaucel
Edouard Vaucel
PAPaule Augereau
Paule Augereau
JCJean-Marc Classe
Jean-Marc Classe

1 May 2018 in Bulletin du Cancer
Verified
Journal Article
Closed access
CLCécile Loaec
Cécile Loaec
EVEdouard Vaucel
Edouard Vaucel
EDEric Darnis
Eric Darnis
PLPatrice Lopes
Patrice Lopes
GSGabrielle Selmes
Gabrielle Selmes
JCJean Marc Classe
Jean Marc Classe

1 June 2018 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
CLCécile Loaec
Cécile Loaec
ABAnne-Sophie Bats
Anne-Sophie Bats
CNCharlotte Ngo
Charlotte Ngo
CCCaroline Cornou
Caroline Cornou
LRLéa Rossi
Léa Rossi
FLFabrice Lecuru
Fabrice Lecuru

1 August 2021 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
CLCécile Loaec
Cécile Loaec
CGCatherine Guérin-Charbonnel
Catherine Guérin-Charbonnel
TVTimothée Vignaud
Timothée Vignaud
JPJacques Paineau
Jacques Paineau
ETEmilie Thibaudeau
Emilie Thibaudeau
FDFrédéric Dumont
Frédéric Dumont

14 December 2022 in International Journal of Gynecological Cancer
Verified
Journal Article
Open access
PDF file
MGMarine Godfroy
Marine Godfroy
CLCécile Loaec
Cécile Loaec
DBDominique Berton
Dominique Berton
CGCatherine Guérin-Charbonnel
Catherine Guérin-Charbonnel
JCJean Marc Classe
Jean Marc Classe
Objectives This retrospective study aimed to assess the efficiency of consolidation chemotherapy after 6 cycles of neoadjuvant chemotherapy and delayed complete surgery on overall survival and progression-free survival among patients with advanced epithelial ovarian cancer. Methods This was a retrospective consecutive study with a propensity score to ensure balance for the baseline characteristics between the study groups. All patients treated for advanced ovarian cancer with 6 cycles of neoadjuvant chemotherapy followed by delayed complete surgery, without post-operative chemotherapy (group 1), or with post-operative chemotherapy (group 2), were included. We evaluated survival and the quality of cytoreductive surgery using the propensity score. Results From 2000 to 2017, 42 patients were included in group 1, and 59 in group 2. The median follow-up was 78 months (confidence interval (CI) 95% (60.1; not computable)). Neither progression-free survival nor overall survival were different between the two groups. The median progression-free survival was 10.2 months (CI 95% (8.8–17.0)) for group 1 and 10.4 months (CI 95% (7.9–12.8)) for group 2 (p=0.57). Five-year overall survival was 21.0% (CI 95% (10.4–42.3)) for group 1 and 26.1% (CI 95% (16.0–42.5)) for group 2 (p=0.73). Conclusions Adding cycles of consolidation chemotherapy after delayed surgery following 6 cycles of neoadjuvant chemotherapy did not demonstrate any survival improvement in patients treated for advanced ovarian cancer not amenable to primary or interval surgery.